EAN 2026: BRILL interim RWE shows high treatment satisfaction with Briumvi

Following treatment with TG Therapeutics’ Briumvi, patients reported improvements in satisfaction and quality of life. Following treatment with TG Therapeutics’ Briumvi, patients reported improvements in satisfaction and quality of life. TG Therapeutics presented the data at EAN 2026 on 27 June. Credit: Piotr Swat / Shutterstock.com Real-world treatment satisfaction and quality of life (QoL) of patients treated with TG Therapeutics’ Briumvi (ublituximab) for relapsing multiple sclerosis (RMS) were shared from the BRILL study. TG Therapeutics continues its efforts to differentiate itself from other anti-CD20 monoclonal antibodies (mAbs) with real-world evidence (RWE), which was presented on 27 June at the 12…

Source: Clinical Trials Arena